MDT stock forecast, quote, news & analysis

Key Takeaways

• MDT advanced roughly 6.8% over the trailing 30 days, from a $85.39 close on July 31, 2026 to $91.23 on August 28, 2026, keeping the move below the 10% threshold.
• Shares have climbed more than 20% over the trailing quarter, supported by accelerating procedure volumes and improving analyst sentiment.
• Cardiac Ablation Solutions (CAS) is the standout growth driver, posting 78% global revenue growth and 124% U.S. growth in fiscal fourth-quarter 2026.
• Multiple analysts raised price targets in August, including TD Cowen ($110) and Needham ($114), while the overall consensus rating stands at "Moderate Buy."
• First-quarter fiscal 2027 results are scheduled for September 1, 2026, with consensus estimates near $1.39 in EPS and $9.47 billion in revenue.
• Medtronic remains a dividend stalwart, with 50 consecutive years of dividend increases and a yield near 3.1%.

Current Market Snapshot

Medtronic shares closed at $91.23 on August 28, 2026, extending a steady advance that has carried the stock from a late-May trough in the low $70s to the low $90s. The 30-day move of roughly 6.8% reflects gradually improving investor confidence in the company's growth trajectory rather than a single event-driven spike, keeping the stock below the threshold typically associated with outsized short-term moves.

The rally has been broad-based and measured. With a market capitalization of roughly $115 billion and a forward price-to-earnings ratio near 15, MDT continues to trade at a discount to the broader medical-products peer group, a gap analysts have cited as a source of potential upside. Dividend income remains a core part of the investment case, with the company's roughly 3.1% yield underpinned by five decades of consecutive increases.

Medtronic (MDT) Business Overview and Competitive Position

Medtronic plc is one of the world's largest medical-technology companies, with a portfolio spanning cardiovascular devices, neuroscience, medical surgical, and diabetes care. The company is legally headquartered in Dublin, Ireland, with operational leadership based in Minneapolis, Minnesota. Its products range from cardiac rhythm management and structural heart therapies to spinal implants, surgical technologies, neuromodulation, and insulin delivery systems.

The company's scale, diversified product lineup, and direct commercial presence across more than 150 markets provide durable competitive advantages, while its research-and-development pipeline targets high-growth areas such as pulsed field ablation (PFA), renal denervation, and surgical robotics. Investors follow MDT both for its dividend stability and for evidence that newer, faster-growing franchises can reaccelerate overall revenue growth.

Recent Developments Driving MDT

Several verified developments shaped MDT's performance over the trailing month. On the analyst front, TD Cowen raised its price target to $110 from $100 on August 28 while maintaining a Buy rating, and Needham lifted its target to $114. Citi also reiterated a Buy rating with a $110 target in mid-August. The average 12-month price target across 27 analysts sits near $98.83, with an overall "Moderate Buy" consensus.

The core fundamental catalyst remains Cardiac Ablation Solutions. In fiscal fourth-quarter 2026 results, CAS delivered 78% worldwide revenue growth and 124% U.S. growth, gaining roughly eight percentage points of U.S. market share, while the pulsed field ablation portfolio grew about 145% globally. Management also cited strong momentum in renal denervation, where the Symplicity system is annualizing near $100 million following expanded Medicare coverage.

Strategically, Medtronic completed its $650 million acquisition of SPR Therapeutics, adding peripheral nerve stimulation therapies for chronic pain. The company is also progressing toward a full separation of its MiniMed diabetes business. Offsetting some of the optimism, a federal jury returned an $88 million verdict against the company in a hernia mesh product-liability case, and tariffs are expected to pressure cost of goods sold by roughly $250 million in fiscal 2027.

Trending AI Robots

Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots from a marketplace that spans hundreds of automated strategies across thousands of tickers. Only the top-performing and most relevant bots are featured in this section, allowing users to filter by strategy, timeframe, and performance metrics. Because each bot operates with its own methodology and risk parameters, traders can compare approaches that range from short-term technical patterns to longer-horizon signals. For investors tracking names like MDT, the page offers a convenient way to explore algorithmic perspectives alongside traditional analysis.

2026 Outlook and What Investors Should Watch

The next major catalyst is Medtronic's first-quarter fiscal 2027 report, scheduled for September 1, 2026, before market open. Consensus estimates call for adjusted EPS near $1.39 and revenue near $9.47 billion, with an extra selling week expected to add a meaningful tailwind to reported growth. Investors will focus on whether CAS can sustain its momentum and whether management reaffirms full-year guidance of 6.75% to 7.25% organic revenue growth and adjusted EPS of $5.90 to $6.00.

Beyond earnings, watch for progress on the MiniMed separation, further renal denervation reimbursement milestones, and updates on surgical-robotics adoption. Macroeconomic factors, including tariffs, foreign-exchange swings, and hospital procedure volumes, remain key swing variables. Medtronic's ability to convert its pipeline momentum into sustained mid-single-digit organic growth will likely determine whether the stock's recent advance can extend further.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations